Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Clermont-Ferrand

About this trial

This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).

Eligibility criteria

Qualifiers

Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or

Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles.

Disqualifiers

Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.),

History of stroke,

Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15/100),

Pain (NRS ≥ 4/10),

Trial design

Treatments tested in this trial

  • Assessment of blood concentrations of microRNAs
  • Chemotherapy-induced peripheral neuropathy (CIPN) - grade
  • Pain assessement
  • Assessment of blood concentrations of neurofilament light chain
  • Neuropathic pain assessment
  • Chemotherapy-induced peripheral neuropathy (CIPN) - severity

Treatment groups

90 Participants
are divided into 2 treatment groups